Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 685-688

  Brouzas, Dimitrios ^a   Charakidas, Antonios ^a   Moschos, Marilita ^a   Koutsandrea, Chryssanthi ^a   Apostolopoulos, Michael ^a   Baltatzis, Stefanos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anterior chamber angle neovascularization; Avastin ; Bevacizumab; Iris neovascularization; Neovascular glaucoma

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB;

ADULT; AGED; ANTERIOR EYE CHAMBER ANGLE; ANTERIOR EYE CHAMBER DISEASE; ANTERIOR EYE CHAMBER NEOVASCULARIZATION; ARTICLE; CASE STUDY; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HEMATOMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; IRIS; MALE; NEOVASCULAR GLAUCOMA; RECURRENT DISEASE; RETINA DETACHMENT; VITREOUS HEMORRHAGE;

EID: 77953416755     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s7698     Document Type: Article

References (15)

1. Parodi M, Iacono P. Photodynamic therapy for neovascular glaucoma. Ophthalmology. 2005;112:1844-1845.
2. Avery R. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin®) treatment. Retina. 2006;26:351-354.
3. Davidorf F, Mouser G, Derick R. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin®) injection. Retina. 2006;26:354-356.
4. Paula S, Jorge R, Costa A, Rodrigues Mde L, Scott IU. Short-term results of intravitreal bevacizumab (Avastin®) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand. 2006;84:556-557.
5. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006;142:158-160.
6. Mason J, Albert M, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina. 2006;26:839-841.
7. Batioǧlu B, Astam N, Özmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008;28:59-61.
8. Lee SJ, Lee JJ, Kin SY, Kim SD. Intravitreal bevacizumab (Avastin®) treatment of neovascular glaucoma in ocular ischemic syndrome. Korean J Ophthalmol. 2009;23:132-134.
9. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. 2009;19:607-612.
10. Gupta V, Jha R, Rao A, Kong G, Sihota R. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol. 2009;19:435-441.
11. Jaissle G, Szurman P, Bartz-Schmit K. Recommendation for the implementation of intravitreal injections - statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd. 2005;225:390-395.
12. Iliev M, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G. Intravitreal bevacizumab (Avastin®) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054-1056.
13. Andrijević-Derk B, Vatavuk Z, Bencić G, Novak-Laus K, Mandić Z. Intravitreal bevacizumab for neovascular glaucoma. Acta Clin Croat. 2008;47:175-179.
14. Martínez-Carpio PA, Bonafonte-Márquez E, Heredia-García CD, Bonafonte-Royo S. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review]. Arch Soc Esp Oftalmol. 2008;83:579-588.
15. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115:1571-1580.